DS
Therapeutic Areas
Agios Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PYRUKYND (mitapivat) | Pyruvate kinase (PK) deficiency — adults | Approved |
| AG-946 | Hemolytic anemias and other indications | Phase 2 |
| Multiple undisclosed preclinical programs | Undisclosed rare diseases | Preclinical |
| IDHIFA (enasidenib) — DIVESTED | Relapsed/refractory AML with IDH2 mutation | Approved |
| TIBSOVO (ivosidenib) — DIVESTED | Relapsed/refractory AML with IDH1 mutation | Approved |
Leadership Team at Agios Pharmaceuticals
BG
Brian Goff
Chief Executive Officer
SG
Sarah Gheuens, M.D., Ph.D.
Chief Medical Officer, Head of R&D
CJ
Cecilia Jones
Chief Financial Officer
TM
Tsveta Milanova
Chief Commercial Officer
KV
Krishnan Viswanadhan, Pharm.D.
Chief Strategy and Operations Officer
EL
Ellen Lopresti
Chief People Officer
JB
Jim Burns
Chief Legal Officer
RB
Rahul Ballal, Ph.D.
Board Member; CEO of Mediar Therapeutics, Inc.
JC
Jeffrey Capello
Independent Board Member; Former CFO of Biogen
KF
Kaye Foster
Independent Board Member; Former SVP Global HR at Onyx Pharmaceuticals